Simvastatin reduces VEGF and NO levels in acute stages of experimental traumatic brain injury

Basit Öğe Kaydı
dc.contributor.authorYuksel, Hatice
dc.contributor.authorYavuz, Ozlem
dc.contributor.authorIs, Merih
dc.contributor.authorComunoglu, Nil
dc.contributor.authorUzum, Gulay
dc.contributor.authorAkyuz, Feyzullah
dc.contributor.authorYildirim, Hayriye Ak
dc.date.accessioned2024-04-24T16:02:00Z
dc.date.available2024-04-24T16:02:00Z
dc.date.issued2013
dc.departmentDicle Üniversitesien_US
dc.description.abstractThis study was undertaken to evaluate the effect of simvastatin, a cholesterol-lowering agent, on vascular endothelial growth factors (VEGFs), nitric oxide (NO) levels and neuroprotection, in rats with experimentally induced traumatic brain injury (TBI). Forty Wistar albino rats were categorized into four groups: sham operated (S), trauma (T), trauma + vehicle (T + V) and trauma + simvastatin (T + S). The T, T + V and T + S groups were subjected to TBI. The T + V group was administered vehicle [ethanol:saline (1/2)] and the T + S group was administered 1 mg/kg of simvastatin 3 h after the injury insult. Blood and brain tissue specimens were obtained 24 h after the trauma to measure VEGFs and NO levels and perform histopathological examinations. The histopathological injury scores of brain tissues were significantly higher in the T group, and simvastatin significantly prevented brain injury in the T + S group. In the T group, significant increases of VEGF levels in serum and brain tissues were noted, which were prevented with simvastatin treatment in the T + S group. The markedly high levels of NO in brain tissues of the T group were decreased by simvastatin treatment in the T + S group. It can be concluded that, as evidenced by histopathological findings, simvastatin treatment improves neuropathology in acute stages of TBI.en_US
dc.identifier.doi10.1007/s10072-013-1411-z
dc.identifier.endpage1946en_US
dc.identifier.issn1590-1874
dc.identifier.issn1590-3478
dc.identifier.issue11en_US
dc.identifier.pmid23543392
dc.identifier.scopus2-s2.0-84888289692
dc.identifier.scopusqualityQ1
dc.identifier.startpage1941en_US
dc.identifier.urihttps://doi.org/10.1007/s10072-013-1411-z
dc.identifier.urihttps://hdl.handle.net/11468/14568
dc.identifier.volume34en_US
dc.identifier.wosWOS:000326861800009
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringer-Verlag Italia Srlen_US
dc.relation.ispartofNeurological Sciences
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSimvastatinen_US
dc.subjectTraumatic Brain Injuryen_US
dc.subjectRaten_US
dc.subjectVegfen_US
dc.subjectNoen_US
dc.titleSimvastatin reduces VEGF and NO levels in acute stages of experimental traumatic brain injuryen_US
dc.titleSimvastatin reduces VEGF and NO levels in acute stages of experimental traumatic brain injury
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu